| Name | Title | Contact Details |
|---|
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Bramalea Denistry is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Koni Ameri Tech Services is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Preferred Healthcare System (PHS) works through insurers and third-party administrators to provide a network of hospitals, physicians, and ancillary providers who can deliver a broad scope of healthcare services. PHS provides this network of hospitals